The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
-
Authors
-
-
Park, Seong Joon1
-
Ryu, Min-Hee
-
Ryoo, Baek-Yeol
-
Park, Young Soo
-
Sohn, Byeong Seok
-
Kim, Hwa Jung
-
Kim, Chan Wook
-
Kim, Ki-Hun
-
Yu, Chang Sik
-
Yook, Jeong Hwan
-
Kim, Byung Sik
-
Kang, Yoon-Koo
-
1
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
,
(North Korea)
- Type
- Published Article
- Journal
-
Annals of Surgical Oncology
- Publisher
-
Springer - Society of Surgical Oncology
- Publication Date
-
Dec 01, 2014
- Volume
-
21
- Issue
-
13
- Pages
-
4211–4217
- Identifiers
-
DOI: 10.1245/s10434-014-3866-4
-
PMID: 24980089
- Source
-
Medline
- License
-
Unknown
Abstract
Surgical resection of residual lesions after disease control with imatinib is likely to be beneficial to patients with recurrent or metastatic GISTs.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 04/18/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at
https://www.ncbi.nlm.nih.gov/pubmed/24980089
